493 related articles for article (PubMed ID: 21890085)
1. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
Storey RF; Becker RC; Harrington RA; Husted S; James SK; Cools F; Steg PG; Khurmi NS; Emanuelsson H; Lim ST; Cannon CP; Katus HA; Wallentin L
Am J Cardiol; 2011 Dec; 108(11):1542-6. PubMed ID: 21890085
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
[TBL] [Abstract][Full Text] [Related]
4. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Held C; Asenblad N; Bassand JP; Becker RC; Cannon CP; Claeys MJ; Harrington RA; Horrow J; Husted S; James SK; Mahaffey KW; Nicolau JC; Scirica BM; Storey RF; Vintila M; Ycas J; Wallentin L
J Am Coll Cardiol; 2011 Feb; 57(6):672-84. PubMed ID: 21194870
[TBL] [Abstract][Full Text] [Related]
5. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
Varenhorst C; Alström U; Scirica BM; Hogue CW; Åsenblad N; Storey RF; Steg PG; Horrow J; Mahaffey KW; Becker RC; James S; Cannon CP; Brandrup-Wognsen G; Wallentin L; Held C
J Am Coll Cardiol; 2012 Oct; 60(17):1623-30. PubMed ID: 23021325
[TBL] [Abstract][Full Text] [Related]
6. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
[TBL] [Abstract][Full Text] [Related]
7. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
Storey RF; Bliden KP; Patil SB; Karunakaran A; Ecob R; Butler K; Teng R; Wei C; Tantry US; Gurbel PA;
J Am Coll Cardiol; 2010 Jul; 56(3):185-93. PubMed ID: 20620737
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor: a novel reversible oral antiplatelet agent.
Nawarskas JJ; Clark SM
Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
[TBL] [Abstract][Full Text] [Related]
9. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
Armstrong PW; Siha H; Fu Y; Westerhout CM; Steg PG; James SK; Storey RF; Horrow J; Katus H; Clemmensen P; Harrington RA; Wallentin L
Circulation; 2012 Jan; 125(3):514-21. PubMed ID: 22179530
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L;
Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
James S; Budaj A; Aylward P; Buck KK; Cannon CP; Cornel JH; Harrington RA; Horrow J; Katus H; Keltai M; Lewis BS; Parikh K; Storey RF; Szummer K; Wojdyla D; Wallentin L
Circulation; 2010 Sep; 122(11):1056-67. PubMed ID: 20805430
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial.
Levin LÅ; Wallentin L; Bernfort L; Andersson D; Storey RF; Bergström G; Lamm CJ; Janzon M; Kaul P
Value Health; 2013 Jun; 16(4):574-80. PubMed ID: 23796291
[TBL] [Abstract][Full Text] [Related]
13. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
Storey RF; Becker RC; Harrington RA; Husted S; James SK; Cools F; Steg PG; Khurmi NS; Emanuelsson H; Cooper A; Cairns R; Cannon CP; Wallentin L
Eur Heart J; 2011 Dec; 32(23):2945-53. PubMed ID: 21804104
[TBL] [Abstract][Full Text] [Related]
14. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Steg PG; James S; Harrington RA; Ardissino D; Becker RC; Cannon CP; Emanuelsson H; Finkelstein A; Husted S; Katus H; Kilhamn J; Olofsson S; Storey RF; Weaver WD; Wallentin L;
Circulation; 2010 Nov; 122(21):2131-41. PubMed ID: 21060072
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
17. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Steg PG; Harrington RA; Emanuelsson H; Katus HA; Mahaffey KW; Meier B; Storey RF; Wojdyla DM; Lewis BS; Maurer G; Wallentin L; James SK;
Circulation; 2013 Sep; 128(10):1055-65. PubMed ID: 23900047
[TBL] [Abstract][Full Text] [Related]
18. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Cornel JH; Becker RC; Goodman SG; Husted S; Katus H; Santoso A; Steg G; Storey RF; Vintila M; Sun JL; Horrow J; Wallentin L; Harrington R; James S
Am Heart J; 2012 Sep; 164(3):334-342.e1. PubMed ID: 22980299
[TBL] [Abstract][Full Text] [Related]
19. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Gurbel PA; Bliden KP; Butler K; Tantry US; Gesheff T; Wei C; Teng R; Antonino MJ; Patil SB; Karunakaran A; Kereiakes DJ; Parris C; Purdy D; Wilson V; Ledley GS; Storey RF
Circulation; 2009 Dec; 120(25):2577-85. PubMed ID: 19923168
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
Husted S
Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
